human fgf2  (Millipore)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Name:
    FGF 2 human
    Description:
    The gene FGF2 fibroblast growth factor 2 is mapped to human chromosome 4q28 FGF 2 is a basic heparin binding growth factor The recombinant human FGF 2 is a 17 2kDa protein containing 154 amino acid residues It is also referred to as BFGF basic fibroblast growth factor
    Catalog Number:
    SRP4037
    Price:
    None
    Applications:
    FGF2 (fibroblast growth factor 2)-human has been used in endothelial colony assay.
    Buy from Supplier


    Structured Review

    Millipore human fgf2
    <t>FGF2</t> dose response for human ES cell self-renewal. Growth curve analysis of H9 cells cultured in CM, UM 4, UM 24, UM 40, UM 80, UM 100, and UM 250 for three passages. 5 × 10 5 cells from CM-cultured H9 cells were plated on Day 0 of passage 1. Cell
    The gene FGF2 fibroblast growth factor 2 is mapped to human chromosome 4q28 FGF 2 is a basic heparin binding growth factor The recombinant human FGF 2 is a 17 2kDa protein containing 154 amino acid residues It is also referred to as BFGF basic fibroblast growth factor
    https://www.bioz.com/result/human fgf2/product/Millipore
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human fgf2 - by Bioz Stars, 2021-04
    95/100 stars

    Images

    1) Product Images from "Basic FGF Support of Human Embryonic Stem Cell Self-Renewal"

    Article Title: Basic FGF Support of Human Embryonic Stem Cell Self-Renewal

    Journal:

    doi: 10.1634/stemcells.2005-0247

    FGF2 dose response for human ES cell self-renewal. Growth curve analysis of H9 cells cultured in CM, UM 4, UM 24, UM 40, UM 80, UM 100, and UM 250 for three passages. 5 × 10 5 cells from CM-cultured H9 cells were plated on Day 0 of passage 1. Cell
    Figure Legend Snippet: FGF2 dose response for human ES cell self-renewal. Growth curve analysis of H9 cells cultured in CM, UM 4, UM 24, UM 40, UM 80, UM 100, and UM 250 for three passages. 5 × 10 5 cells from CM-cultured H9 cells were plated on Day 0 of passage 1. Cell

    Techniques Used: Cell Culture

    FGF2 Stability. Different starting concentrations of FGF2 added to conditioned or unconditioned medium were analyzed for remaining FGF2 concentrations after overnight incubation at 4° C (Blue Bars) or on H1 cells at 37° C (Red Bars). Samples
    Figure Legend Snippet: FGF2 Stability. Different starting concentrations of FGF2 added to conditioned or unconditioned medium were analyzed for remaining FGF2 concentrations after overnight incubation at 4° C (Blue Bars) or on H1 cells at 37° C (Red Bars). Samples

    Techniques Used: Incubation

    Morphology of human ES cells grown in high FGF2 concentrations. 5× phase contrast images show representative morphology of H14 cells maintained for 5 days in A) CM, B) UM, C) UM 40, or D) UM 100. Arrows identify centralized regions of differentiation
    Figure Legend Snippet: Morphology of human ES cells grown in high FGF2 concentrations. 5× phase contrast images show representative morphology of H14 cells maintained for 5 days in A) CM, B) UM, C) UM 40, or D) UM 100. Arrows identify centralized regions of differentiation

    Techniques Used:

    2) Product Images from "β-catenin perturbations control differentiation programs in mouse embryonic stem cells"

    Article Title: β-catenin perturbations control differentiation programs in mouse embryonic stem cells

    Journal: bioRxiv

    doi: 10.1101/2020.05.15.098137

    Chemical perturbation of the Wnt/β-catenin in EpiSC derivation in vitro . A Experimental scheme of Epiblast differentiation. Dual reporter ESCs cultured in FBS/L and pre-treated for 48 hrs with DMSO and Chiron (1-3 µM), or in 2i/L for 3 passages, were seeded on fibronectin in NDiff227 supplemented with different combination of drugs (ActivinA+FGF2+DMSO (AFD); ActivinA+FGF2+Ch1µM (AFC1); ActivinA+FGF2+Ch3µM (AFC3); Ch1µM (C1); Ch1µM+XAV2µM (C1X2); Ch3µM (C3); Ch3µM+XAV2µM (C3X2)). The GFP signal from the EpiSC marker was measured by flow cytometry every 24 hrs for 4 consecutive days. After the first 2 days, the media was changed, and the drugs were refreshed. B-E Percentage of GFP+ cells calculated over the total amount of living cells in DMSO (B) , Ch1µM (C) , Ch3µM (D) and 2i/L (E) pre-cultured dual reporter ESCs. Histograms from Day 0 and Day 4 of each condition are shown as insets. Data are means±SEM (n=2, B (Day1, Day3 AFD, Day4 AFD), C (Day 1), D (Day1, Day3 AFC3), E (Day0, Day1 AFC3-C3X2); n=3, B (Day0, Day2, Day3 AFC1-AFC3-C1-C1X2-C3-C3X2, Day4 AFC1-AFC3-C1-C1X2-C3-C3X2), C (Day0, Day2 AFD-AFC1-C1X2, Day3, Day4), D (Day0, Day2 AFD-AFC3-C3X2, Day3 AFD-C3-C3X2, Day4), E (Day1 AFD, Day2 AFD-AFC3-C3X2, Day3, Day4); n=6, C (Day2 C1), D (Day2 C3), E (Day1 C3, Day2 C3). p-values from one-way ANOVA are shown across samples for each day. Dots represent individual data with similar values overlapping. Colour-blind safe combinations were selected using colorbrewer2 ( https://colorbrewer2.org/#type=sequential scheme=BuGn n=3 ).
    Figure Legend Snippet: Chemical perturbation of the Wnt/β-catenin in EpiSC derivation in vitro . A Experimental scheme of Epiblast differentiation. Dual reporter ESCs cultured in FBS/L and pre-treated for 48 hrs with DMSO and Chiron (1-3 µM), or in 2i/L for 3 passages, were seeded on fibronectin in NDiff227 supplemented with different combination of drugs (ActivinA+FGF2+DMSO (AFD); ActivinA+FGF2+Ch1µM (AFC1); ActivinA+FGF2+Ch3µM (AFC3); Ch1µM (C1); Ch1µM+XAV2µM (C1X2); Ch3µM (C3); Ch3µM+XAV2µM (C3X2)). The GFP signal from the EpiSC marker was measured by flow cytometry every 24 hrs for 4 consecutive days. After the first 2 days, the media was changed, and the drugs were refreshed. B-E Percentage of GFP+ cells calculated over the total amount of living cells in DMSO (B) , Ch1µM (C) , Ch3µM (D) and 2i/L (E) pre-cultured dual reporter ESCs. Histograms from Day 0 and Day 4 of each condition are shown as insets. Data are means±SEM (n=2, B (Day1, Day3 AFD, Day4 AFD), C (Day 1), D (Day1, Day3 AFC3), E (Day0, Day1 AFC3-C3X2); n=3, B (Day0, Day2, Day3 AFC1-AFC3-C1-C1X2-C3-C3X2, Day4 AFC1-AFC3-C1-C1X2-C3-C3X2), C (Day0, Day2 AFD-AFC1-C1X2, Day3, Day4), D (Day0, Day2 AFD-AFC3-C3X2, Day3 AFD-C3-C3X2, Day4), E (Day1 AFD, Day2 AFD-AFC3-C3X2, Day3, Day4); n=6, C (Day2 C1), D (Day2 C3), E (Day1 C3, Day2 C3). p-values from one-way ANOVA are shown across samples for each day. Dots represent individual data with similar values overlapping. Colour-blind safe combinations were selected using colorbrewer2 ( https://colorbrewer2.org/#type=sequential scheme=BuGn n=3 ).

    Techniques Used: In Vitro, Cell Culture, Marker, Flow Cytometry

    Dual-input control of β-catenin doses in EpiSC derivation in vitro . A Dual-input regulation system consisting of the doxycycline responsive element and the conditionally destabilised mCherryβ-catenin S33Y module. Doxycycline (Doxy) and trimethoprim (TMP) allow mCherryβ-catenin S33Y transcription initiation and protein stabilisation, respectively. (A, inset) Flow cytometry profile of C1 ESCs treated for 24 hrs with TMP10µM and the indicated concentrations of Doxy. B, C Experimental scheme ESC to EpiSC differentiation. FBS/L and 2i/L C1 ESCs were pre-treated either with DMSO (B) or TMP10µM and Doxy10-100ng/mL (C) . Following 48 hrs of treatment, cells were seeded on fibronectin in NDiff227 and exposed to ActvinA/FGF2 and different combination of DMSO, Doxy and TMP for 4 days before being collected for RNA extraction. After 2 days, the media was changed, and the drugs were refreshed. D, E Fgf5 mRNA levels measured in FBS/L (D) and 2i/L (E) C1 ESCs, after 4 days of differentiation in NDiff227+ActivinA/FGF2 and different combination of DMSO, Doxy and TMP. Data are means±SEM (n=7, D (T0, Doxy10-100ng/mL “During Differentiation”, Doxy10ng/mL T0, Doxy100ng/mL T0, Doxy100ng/mL “Before” ad Doxy100ng/mL “Always”); n=6, D (Doxy10ng/mL “Before”); n=5, D (TMP10µM “During Differentiation”); n=2, E). p-values from two-tailed unpaired t test computed by comparing each sample with C1 TMP10µM “During Differentiation” are shown, *p
    Figure Legend Snippet: Dual-input control of β-catenin doses in EpiSC derivation in vitro . A Dual-input regulation system consisting of the doxycycline responsive element and the conditionally destabilised mCherryβ-catenin S33Y module. Doxycycline (Doxy) and trimethoprim (TMP) allow mCherryβ-catenin S33Y transcription initiation and protein stabilisation, respectively. (A, inset) Flow cytometry profile of C1 ESCs treated for 24 hrs with TMP10µM and the indicated concentrations of Doxy. B, C Experimental scheme ESC to EpiSC differentiation. FBS/L and 2i/L C1 ESCs were pre-treated either with DMSO (B) or TMP10µM and Doxy10-100ng/mL (C) . Following 48 hrs of treatment, cells were seeded on fibronectin in NDiff227 and exposed to ActvinA/FGF2 and different combination of DMSO, Doxy and TMP for 4 days before being collected for RNA extraction. After 2 days, the media was changed, and the drugs were refreshed. D, E Fgf5 mRNA levels measured in FBS/L (D) and 2i/L (E) C1 ESCs, after 4 days of differentiation in NDiff227+ActivinA/FGF2 and different combination of DMSO, Doxy and TMP. Data are means±SEM (n=7, D (T0, Doxy10-100ng/mL “During Differentiation”, Doxy10ng/mL T0, Doxy100ng/mL T0, Doxy100ng/mL “Before” ad Doxy100ng/mL “Always”); n=6, D (Doxy10ng/mL “Before”); n=5, D (TMP10µM “During Differentiation”); n=2, E). p-values from two-tailed unpaired t test computed by comparing each sample with C1 TMP10µM “During Differentiation” are shown, *p

    Techniques Used: In Vitro, Flow Cytometry, RNA Extraction, Two Tailed Test

    3) Product Images from "High Yield of Adult Oligodendrocyte Lineage Cells Obtained from Meningeal Biopsy"

    Article Title: High Yield of Adult Oligodendrocyte Lineage Cells Obtained from Meningeal Biopsy

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2017.00703

    Oligodendrocyte differentiation protocol. (A) Schematic representation of spinal cord meningeal biopsy isolation for organotypic culture. Spinal cord was dissected from adult SD rat and 1 cm of meningeal tissue was isolated and plated in neurosphere expansion medium (NS, day 0). (B) Time course representation of the oligodendrocyte differentiation protocol from spinal cord meningeal biopsy. From day 0 to day 10: neurosphere expansion (NS), from day 10 to day 20: oligosphere culture (Step Go1); from day 20 to day 30: oligodendrocyte differentiation (Step Go2); from day 30 to day 33: oligodendrocyte maturation (Step Go3). Images show meningeal-derived differentiating oligodendrocyte morphology at each stage of the protocol. Insets in (B) are higher magnification images of representative cells in the boxes. Pictures in (B) are brightfield images. (C) Number of meningeal-derived cells in culture, calculated for every experimental replicate ( n = 4), present at each stage of the differentiation protocol. Data are presented as mean ± SEM. NSCs: neural stem cells; FGF2: human basic fibroblast growth factor; EGF: epidermal growth factor; PDGF-AA: platelet-derived growth factor type AA; T3: 3,3′,5-triiodo- L -thyronine. Scale bars: 50 μm.
    Figure Legend Snippet: Oligodendrocyte differentiation protocol. (A) Schematic representation of spinal cord meningeal biopsy isolation for organotypic culture. Spinal cord was dissected from adult SD rat and 1 cm of meningeal tissue was isolated and plated in neurosphere expansion medium (NS, day 0). (B) Time course representation of the oligodendrocyte differentiation protocol from spinal cord meningeal biopsy. From day 0 to day 10: neurosphere expansion (NS), from day 10 to day 20: oligosphere culture (Step Go1); from day 20 to day 30: oligodendrocyte differentiation (Step Go2); from day 30 to day 33: oligodendrocyte maturation (Step Go3). Images show meningeal-derived differentiating oligodendrocyte morphology at each stage of the protocol. Insets in (B) are higher magnification images of representative cells in the boxes. Pictures in (B) are brightfield images. (C) Number of meningeal-derived cells in culture, calculated for every experimental replicate ( n = 4), present at each stage of the differentiation protocol. Data are presented as mean ± SEM. NSCs: neural stem cells; FGF2: human basic fibroblast growth factor; EGF: epidermal growth factor; PDGF-AA: platelet-derived growth factor type AA; T3: 3,3′,5-triiodo- L -thyronine. Scale bars: 50 μm.

    Techniques Used: Isolation, Derivative Assay

    Related Articles

    Recombinant:

    Article Title: Tumor Necrosis Factor–Related Apoptosis‐Inducing Ligand ( TRAIL) Promotes Angiogenesis and Ischemia‐Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide–Dependent Mechanisms
    Article Snippet: .. Unless indicated, 10 ng/mL recombinant human TRAIL (R & D Systems), 50 ng/mL human FGF‐2 (Sigma Aldrich), 1 μmol/L l ‐NG‐nitroarginine methyl ester (l ‐NAME; Sigma Aldrich), and 200 U/mL PEG‐catalase (Sigma Aldrich) were used in all experiments. ..

    Article Title: VEGF and FGF-2 delivery from spinal cord bridges to enhance angiogenesis following injury
    Article Snippet: .. Proteins were encapsulated into the microspheres by emulsifying a protein solution (17 µl), containing VEGF (recombinant mouse VEGF-165, Prospec, Rehovot, Israel) or FGF-2 (recombinant human FGF-2, Chemicon, Billerica, Massachusetts), 700 µg bovine serum albumin (BSA), 50 mg/mL sucrose, and MgCO3 (3% wt of BSA), with 500 µL 3 wt% PLG in dichloromethane using sonication at 40 watt for 15 s on ice. .. This first emulsion was sequentially frozen in liquid nitrogen for 4 sec in order to freeze the aqueous protein solution part without freezing the polymer solution.

    Article Title: FIBROBLAST GROWTH FACTOR 2 ENHANCES STRIATAL AND NIGRAL NEUROGENESIS IN THE ACUTE 1-METHYL-4-PHENYL-1,2,3, 6-TETRAHYDROPYRIDINE MODEL OF PARKINSON'S DISEASE
    Article Snippet: MPTP (20 mg/kg free base, Sigma, St. Louis, MO, USA) dissolved in saline was administered intraperitoneally to male C57BL/6 mice (8-week-old, Charles River Laboratories, Wilmington, MA, USA) every 2 h for four doses. .. Following the last MPTP injection, mice were injected intraperitoneally with either PBS alone or recombinant human FGF-2 (38 μ g/kg, Chemicon, Temecula, CA, USA) in PBS daily for 10 days (days 0–10 after MPTP or saline administration). ..

    Article Title: Transcriptional regulation of the IL-13Rα2 gene in human lung fibroblasts
    Article Snippet: Fibs were cultured in low glucose Dulbecco’s modified Eagle’s medium and epithelial cells were cultured in RPMI-1640 medium (both purchased from Invitrogen) and supplemented with 10% fetal bovine serum (Hyclone), 100 units/ml penicillin (Gibco), and 100 μg/ml streptomycin (Invitrogen). .. Recombinant human IL-13, FGF-2, PDGF, TNF-α, and TGF-β, as well as LPA, were purchased from Millipore. .. PGE2 , forskolin, butaprost, Act D, LPA, PI3 kinase inhibitor (LY294002) and AKT inhibitor (triciribine) were purchased from Cayman Chemicals.

    Article Title: Comparative Evaluation of TRAIL, FGF-2 and VEGF-A-Induced Angiogenesis In Vitro and In Vivo
    Article Snippet: Human recombinant TRAIL was purchased from R & D Systems (Minneapolis, MN, USA). .. Human recombinant VEGF-A and FGF-2 were purchased from Sigma-Aldrich (St. Louis, MO, USA). ..

    Sonication:

    Article Title: VEGF and FGF-2 delivery from spinal cord bridges to enhance angiogenesis following injury
    Article Snippet: .. Proteins were encapsulated into the microspheres by emulsifying a protein solution (17 µl), containing VEGF (recombinant mouse VEGF-165, Prospec, Rehovot, Israel) or FGF-2 (recombinant human FGF-2, Chemicon, Billerica, Massachusetts), 700 µg bovine serum albumin (BSA), 50 mg/mL sucrose, and MgCO3 (3% wt of BSA), with 500 µL 3 wt% PLG in dichloromethane using sonication at 40 watt for 15 s on ice. .. This first emulsion was sequentially frozen in liquid nitrogen for 4 sec in order to freeze the aqueous protein solution part without freezing the polymer solution.

    Injection:

    Article Title: FIBROBLAST GROWTH FACTOR 2 ENHANCES STRIATAL AND NIGRAL NEUROGENESIS IN THE ACUTE 1-METHYL-4-PHENYL-1,2,3, 6-TETRAHYDROPYRIDINE MODEL OF PARKINSON'S DISEASE
    Article Snippet: MPTP (20 mg/kg free base, Sigma, St. Louis, MO, USA) dissolved in saline was administered intraperitoneally to male C57BL/6 mice (8-week-old, Charles River Laboratories, Wilmington, MA, USA) every 2 h for four doses. .. Following the last MPTP injection, mice were injected intraperitoneally with either PBS alone or recombinant human FGF-2 (38 μ g/kg, Chemicon, Temecula, CA, USA) in PBS daily for 10 days (days 0–10 after MPTP or saline administration). ..

    Mouse Assay:

    Article Title: FIBROBLAST GROWTH FACTOR 2 ENHANCES STRIATAL AND NIGRAL NEUROGENESIS IN THE ACUTE 1-METHYL-4-PHENYL-1,2,3, 6-TETRAHYDROPYRIDINE MODEL OF PARKINSON'S DISEASE
    Article Snippet: MPTP (20 mg/kg free base, Sigma, St. Louis, MO, USA) dissolved in saline was administered intraperitoneally to male C57BL/6 mice (8-week-old, Charles River Laboratories, Wilmington, MA, USA) every 2 h for four doses. .. Following the last MPTP injection, mice were injected intraperitoneally with either PBS alone or recombinant human FGF-2 (38 μ g/kg, Chemicon, Temecula, CA, USA) in PBS daily for 10 days (days 0–10 after MPTP or saline administration). ..

    Incubation:

    Article Title: Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1)
    Article Snippet: The reaction was incubated at 20 °C for 1 h. Next, the reaction mixture was loaded onto the HiTrap CM Sepharose column, the unreacted payload was washed out using 25 mM monosodium phosphate pH 7.0 with 10 mM Na2 SO4, and finally, the conjugate was eluted with the same buffer containing 0.5 M NaCl. .. Stability in Human SerumFGF2 and FGF2 conjugates (1 μg/mL) were incubated at 37 °C for different time periods (0, 48, 72, 96, and 120 h) in human serum (H4522, Sigma-Aldrich) in the absence of heparin. .. Then samples were analyzed by immunoblotting with mouse anti-FGF2 (sc-74412) and donkey antimouse IgG-HRP (sc-2318) antibodies from Santa Cruz Biotechnology (Dallas, TX).

    Article Title: Glucose-Dependent Insulinotropic Polypeptide Is Expressed in Adult Hippocampus and Induces Progenitor Cell Proliferation
    Article Snippet: .. AHPs were seeded at 0.2 × 104 cells/cm2 on 24-well plates in culture medium containing human FGF-2 (20 ng/ml; a well documented proliferative agent for AHPs) and grown for 48 h. After an additional 48 h of growth without FGF-2, cells were incubated with FGF-2 (20 ng/ml; four experiments), porcine GIP (Sigma) alone (eight experiments), or in combination with FGF-2 (eight experiments) for 48 h. Controls were cells grown without FGF-2. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Millipore heparin stabilized fgf2
    Cubn binds Fgf8 with high affinity and contributes to Fgf8 signaling in vitro . A, co-immunoprecipitation ( IP ) of Fgf8 and the structurally similar Fgf17 with Cubn; <t>Fgf2,</t> Fgf3, or Fgf15 do not interact with Cubn. B, SPR analysis on immobilized Cubn. Fgf8a
    Heparin Stabilized Fgf2, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/heparin stabilized fgf2/product/Millipore
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    heparin stabilized fgf2 - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    95
    Millipore fgf 2
    Neurite ingrowth with bridge at 6 weeks post implantation. A) Neurofilament stain (brown) of bridge implanted with the highest <t>VEGF/FGF-2</t> protein dose. The red dotted line marks the contours of the bridge at the implant site. Scale bar: 500 µm.
    Fgf 2, supplied by Millipore, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fgf 2/product/Millipore
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    fgf 2 - by Bioz Stars, 2021-04
    95/100 stars
      Buy from Supplier

    94
    Millipore fgf23
    Effects of nephrectomy and/or high phosphorus diet on serum levels of systemic bone formation and skeletal markers. Serum levels of ( a ) Calcium, ( b ) sclerostin, ( c ) phosphorus, ( d ) creatinine, ( e ) <t>FGF23,</t> and ( f ) iPTH were measured at days 19 and 26 post-nephrectomy. *Significant at p
    Fgf23, supplied by Millipore, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fgf23/product/Millipore
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    fgf23 - by Bioz Stars, 2021-04
    94/100 stars
      Buy from Supplier

    Image Search Results


    Cubn binds Fgf8 with high affinity and contributes to Fgf8 signaling in vitro . A, co-immunoprecipitation ( IP ) of Fgf8 and the structurally similar Fgf17 with Cubn; Fgf2, Fgf3, or Fgf15 do not interact with Cubn. B, SPR analysis on immobilized Cubn. Fgf8a

    Journal: The Journal of Biological Chemistry

    Article Title: Cubilin, a High Affinity Receptor for Fibroblast Growth Factor 8, Is Required for Cell Survival in the Developing Vertebrate Head *

    doi: 10.1074/jbc.M113.451070

    Figure Lengend Snippet: Cubn binds Fgf8 with high affinity and contributes to Fgf8 signaling in vitro . A, co-immunoprecipitation ( IP ) of Fgf8 and the structurally similar Fgf17 with Cubn; Fgf2, Fgf3, or Fgf15 do not interact with Cubn. B, SPR analysis on immobilized Cubn. Fgf8a

    Article Snippet: Overnight serum-starved cells were incubated for 5 min with 5 ng/ml Fgf8b (catalog no. 423-F8, R & D Systems) or 5 ng/ml heparin-stabilized FGF2 (F9786; Sigma).

    Techniques: In Vitro, Immunoprecipitation, SPR Assay

    Neurite ingrowth with bridge at 6 weeks post implantation. A) Neurofilament stain (brown) of bridge implanted with the highest VEGF/FGF-2 protein dose. The red dotted line marks the contours of the bridge at the implant site. Scale bar: 500 µm.

    Journal: Journal of biomedical materials research. Part A

    Article Title: VEGF and FGF-2 delivery from spinal cord bridges to enhance angiogenesis following injury

    doi: 10.1002/jbm.a.33112

    Figure Lengend Snippet: Neurite ingrowth with bridge at 6 weeks post implantation. A) Neurofilament stain (brown) of bridge implanted with the highest VEGF/FGF-2 protein dose. The red dotted line marks the contours of the bridge at the implant site. Scale bar: 500 µm.

    Article Snippet: Proteins were encapsulated into the microspheres by emulsifying a protein solution (17 µl), containing VEGF (recombinant mouse VEGF-165, Prospec, Rehovot, Israel) or FGF-2 (recombinant human FGF-2, Chemicon, Billerica, Massachusetts), 700 µg bovine serum albumin (BSA), 50 mg/mL sucrose, and MgCO3 (3% wt of BSA), with 500 µL 3 wt% PLG in dichloromethane using sonication at 40 watt for 15 s on ice.

    Techniques: Staining

    Protein release from bridge. Bridges were fabricated with VEGF (filled line) or FGF-2 (dotted line) in three different manners: mixing only (squares), encapsulation only (triangles), or a combination of both encapsulation and mixing (circles). The amount

    Journal: Journal of biomedical materials research. Part A

    Article Title: VEGF and FGF-2 delivery from spinal cord bridges to enhance angiogenesis following injury

    doi: 10.1002/jbm.a.33112

    Figure Lengend Snippet: Protein release from bridge. Bridges were fabricated with VEGF (filled line) or FGF-2 (dotted line) in three different manners: mixing only (squares), encapsulation only (triangles), or a combination of both encapsulation and mixing (circles). The amount

    Article Snippet: Proteins were encapsulated into the microspheres by emulsifying a protein solution (17 µl), containing VEGF (recombinant mouse VEGF-165, Prospec, Rehovot, Israel) or FGF-2 (recombinant human FGF-2, Chemicon, Billerica, Massachusetts), 700 µg bovine serum albumin (BSA), 50 mg/mL sucrose, and MgCO3 (3% wt of BSA), with 500 µL 3 wt% PLG in dichloromethane using sonication at 40 watt for 15 s on ice.

    Techniques:

    VEGF and FGF-2 activity during in vitro release. Phosphorylation of (A) VEGF and (B) FGF-2 receptors was assessed by western blot. Legend: 1. control (100 ng/ml VEGF or 50 ng/ml FGF-2), 2. mixing 24 hours, 3. encapsulation 24 hours, 4. mixing 5 days,

    Journal: Journal of biomedical materials research. Part A

    Article Title: VEGF and FGF-2 delivery from spinal cord bridges to enhance angiogenesis following injury

    doi: 10.1002/jbm.a.33112

    Figure Lengend Snippet: VEGF and FGF-2 activity during in vitro release. Phosphorylation of (A) VEGF and (B) FGF-2 receptors was assessed by western blot. Legend: 1. control (100 ng/ml VEGF or 50 ng/ml FGF-2), 2. mixing 24 hours, 3. encapsulation 24 hours, 4. mixing 5 days,

    Article Snippet: Proteins were encapsulated into the microspheres by emulsifying a protein solution (17 µl), containing VEGF (recombinant mouse VEGF-165, Prospec, Rehovot, Israel) or FGF-2 (recombinant human FGF-2, Chemicon, Billerica, Massachusetts), 700 µg bovine serum albumin (BSA), 50 mg/mL sucrose, and MgCO3 (3% wt of BSA), with 500 µL 3 wt% PLG in dichloromethane using sonication at 40 watt for 15 s on ice.

    Techniques: Activity Assay, In Vitro, Western Blot

    Endothelial cell infiltration in bridge at 6 weeks post implantation. A) RECA stain (brown): from left to right: bridge containing 4 µg of VEGF encapsulated within microspheres and 2 µg of FGF-2 and VEGF mixed (high protein), and bridge

    Journal: Journal of biomedical materials research. Part A

    Article Title: VEGF and FGF-2 delivery from spinal cord bridges to enhance angiogenesis following injury

    doi: 10.1002/jbm.a.33112

    Figure Lengend Snippet: Endothelial cell infiltration in bridge at 6 weeks post implantation. A) RECA stain (brown): from left to right: bridge containing 4 µg of VEGF encapsulated within microspheres and 2 µg of FGF-2 and VEGF mixed (high protein), and bridge

    Article Snippet: Proteins were encapsulated into the microspheres by emulsifying a protein solution (17 µl), containing VEGF (recombinant mouse VEGF-165, Prospec, Rehovot, Israel) or FGF-2 (recombinant human FGF-2, Chemicon, Billerica, Massachusetts), 700 µg bovine serum albumin (BSA), 50 mg/mL sucrose, and MgCO3 (3% wt of BSA), with 500 µL 3 wt% PLG in dichloromethane using sonication at 40 watt for 15 s on ice.

    Techniques: Staining

    Protein encapsulation efficiency and protein retention after leaching. A) VEGF and FGF-2 encapsulation efficiency after microsphere encapsulation and collection. B) VEGF and FGF-2 retention after leaching bridges for 1 h. Proteins were incorporated using

    Journal: Journal of biomedical materials research. Part A

    Article Title: VEGF and FGF-2 delivery from spinal cord bridges to enhance angiogenesis following injury

    doi: 10.1002/jbm.a.33112

    Figure Lengend Snippet: Protein encapsulation efficiency and protein retention after leaching. A) VEGF and FGF-2 encapsulation efficiency after microsphere encapsulation and collection. B) VEGF and FGF-2 retention after leaching bridges for 1 h. Proteins were incorporated using

    Article Snippet: Proteins were encapsulated into the microspheres by emulsifying a protein solution (17 µl), containing VEGF (recombinant mouse VEGF-165, Prospec, Rehovot, Israel) or FGF-2 (recombinant human FGF-2, Chemicon, Billerica, Massachusetts), 700 µg bovine serum albumin (BSA), 50 mg/mL sucrose, and MgCO3 (3% wt of BSA), with 500 µL 3 wt% PLG in dichloromethane using sonication at 40 watt for 15 s on ice.

    Techniques:

    Brachyury knockdown inhibited FGFR/MEK/ERK signaling and blocked the effects of FGF2 on apoptosis and growth of chordoma cells. ( A ) JHC7, UCH1 and UCH2 cells were cultured in triplicate in FBS-free medium and transfected with scramble shRNA or brachyury shRNA for 48h. FGF2 secreted into the medium was measured by ELISA and normalized to protein measured in cell lysates. Values represent means ± SD ( n = 3). ( B ) JHC7, UCH1 and UCH2 cells were transfected with scramble shRNA or brachyury shRNA for 24h, then were starved overnight and treated with FGF2 (100ng/ml) for 10min. Cell protein extracts were used for western blot analysis of brachyury, FGFR2 and p-FRS2-α. Representative bands from three independent experiments are shown. ( C ) JHC7, UCH1 and UCH2 cells were transfected with scramble shRNA or brachyury shRNA for 48h. Cell protein extracts were used for western blot analysis of brachyury, p-MEK 1/2, MEK, p-ERK 1/2 and ERK 1/2. Representative bands from three independent experiments are shown. ( D , E and F ) JHC7, UCH1 and UCH2 cells were seeded at 96-well plate and transfected with scramble shRNA or brachyury shRNA for 24h, then were starved overnight and treated with FGF2 (100ng/ml) for 48h (D and E) or 3 days (F). Caspase 3 activity (D), DNA fragmentation (E) and cell growth (F) were measured by the Caspase-GloR 3/7 assay, a DNA Cell Death Detection ELISA PLUS Kit and MTS assay. Values represent means ± SD ( n = 3). * P

    Journal: Carcinogenesis

    Article Title: The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival

    doi: 10.1093/carcin/bgu014

    Figure Lengend Snippet: Brachyury knockdown inhibited FGFR/MEK/ERK signaling and blocked the effects of FGF2 on apoptosis and growth of chordoma cells. ( A ) JHC7, UCH1 and UCH2 cells were cultured in triplicate in FBS-free medium and transfected with scramble shRNA or brachyury shRNA for 48h. FGF2 secreted into the medium was measured by ELISA and normalized to protein measured in cell lysates. Values represent means ± SD ( n = 3). ( B ) JHC7, UCH1 and UCH2 cells were transfected with scramble shRNA or brachyury shRNA for 24h, then were starved overnight and treated with FGF2 (100ng/ml) for 10min. Cell protein extracts were used for western blot analysis of brachyury, FGFR2 and p-FRS2-α. Representative bands from three independent experiments are shown. ( C ) JHC7, UCH1 and UCH2 cells were transfected with scramble shRNA or brachyury shRNA for 48h. Cell protein extracts were used for western blot analysis of brachyury, p-MEK 1/2, MEK, p-ERK 1/2 and ERK 1/2. Representative bands from three independent experiments are shown. ( D , E and F ) JHC7, UCH1 and UCH2 cells were seeded at 96-well plate and transfected with scramble shRNA or brachyury shRNA for 24h, then were starved overnight and treated with FGF2 (100ng/ml) for 48h (D and E) or 3 days (F). Caspase 3 activity (D), DNA fragmentation (E) and cell growth (F) were measured by the Caspase-GloR 3/7 assay, a DNA Cell Death Detection ELISA PLUS Kit and MTS assay. Values represent means ± SD ( n = 3). * P

    Article Snippet: Human FGF2 ELISA Kit was from Sigma–Aldrich Co. LLC (St Louis, MO).

    Techniques: Cell Culture, Transfection, shRNA, Enzyme-linked Immunosorbent Assay, Western Blot, Activity Assay, MTS Assay

    Expressions of FGF2 and FGFR/MEK/ERK/brachyury in chordoma cells. ( A ) Protein extracts from JHC7, UCH1 and UCH2 cells were used for western blot analysis of FGFR1, 2, 3 and 4, MEK phosphorylation (p-MEK 1/2), MEK 1/2, ERK phosphorylation (p-ERK 1/2), ERK (ERK 1/2) and brachyury. ( B ) Human foreskin fibroblast BJ cells (as a control) and chordoma cells (JHC7, UCH1 and UCH2) were cultured for 3 days in serum-free medium. FGF2 secreted into the medium was measured by ELISA and normalized to protein measured in cell lysates. ( C ) JHC7, UCH1 and UCH2 cells was incubated in serum-free medium (control) and treated with neutralizing antibody to FGF2 (FGF2 antibody, 20 µg/ml) or normal IgG (20 µg/ml) for 48h. Protein extracts from cells were used for western blot analysis of FGF2, MEK phosphorylation (p-MEK 1/2), MEK 1/2, ERK phosphorylation (p-ERK 1/2), ERK (ERK 1/2) and brachyury. ( D , E and F ) JHC7, UCH1 and UCH2 cells were incubated in triplicate serum-free medium (control) and treated with neutralizing antibody to FGF2 (FGF2 antibody, 20 µg/ml) or normal IgG (20 µg/ml) as negative control for 48h (D E) or 5 days (F). Caspase 3 activity (D), DNA fragmentation (E) and cell growth (F) were measured by the Caspase-GloR 3/7 assay, a DNA Cell Death Detection ELISA PLUS Kit and MTS assay. Values represent means ± SD ( n = 3). * P

    Journal: Carcinogenesis

    Article Title: The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival

    doi: 10.1093/carcin/bgu014

    Figure Lengend Snippet: Expressions of FGF2 and FGFR/MEK/ERK/brachyury in chordoma cells. ( A ) Protein extracts from JHC7, UCH1 and UCH2 cells were used for western blot analysis of FGFR1, 2, 3 and 4, MEK phosphorylation (p-MEK 1/2), MEK 1/2, ERK phosphorylation (p-ERK 1/2), ERK (ERK 1/2) and brachyury. ( B ) Human foreskin fibroblast BJ cells (as a control) and chordoma cells (JHC7, UCH1 and UCH2) were cultured for 3 days in serum-free medium. FGF2 secreted into the medium was measured by ELISA and normalized to protein measured in cell lysates. ( C ) JHC7, UCH1 and UCH2 cells was incubated in serum-free medium (control) and treated with neutralizing antibody to FGF2 (FGF2 antibody, 20 µg/ml) or normal IgG (20 µg/ml) for 48h. Protein extracts from cells were used for western blot analysis of FGF2, MEK phosphorylation (p-MEK 1/2), MEK 1/2, ERK phosphorylation (p-ERK 1/2), ERK (ERK 1/2) and brachyury. ( D , E and F ) JHC7, UCH1 and UCH2 cells were incubated in triplicate serum-free medium (control) and treated with neutralizing antibody to FGF2 (FGF2 antibody, 20 µg/ml) or normal IgG (20 µg/ml) as negative control for 48h (D E) or 5 days (F). Caspase 3 activity (D), DNA fragmentation (E) and cell growth (F) were measured by the Caspase-GloR 3/7 assay, a DNA Cell Death Detection ELISA PLUS Kit and MTS assay. Values represent means ± SD ( n = 3). * P

    Article Snippet: Human FGF2 ELISA Kit was from Sigma–Aldrich Co. LLC (St Louis, MO).

    Techniques: Western Blot, Cell Culture, Enzyme-linked Immunosorbent Assay, Incubation, Negative Control, Activity Assay, MTS Assay

    The inhibition of FGFR reduced MEK/ERK phosphorylation, brachyury expression and the growth of chordoma cells. ( A ) JHC7, UCH1 and UCH2 cells were seeded in six-well plates at density of 2×10 5 cells per well for 24h, then cells were starved overnight and treated with FGF2 (100ng/ml) for 10min following PD173074 treatment (1 µM) for 30min. Cell protein extracts were used for western blot analysis of FGFR2 and its phosphorylation (p-FRS2). Representative bands from three independent experiments are shown. ( B ) JHC7, UCH1 and UCH2 cells were treated with FGFR inhibitor (PD173074) at dose of 0.5, 1 and 2 µM for 48h. Cell protein extracts were used for western blot analysis of p-FRS2-α, FGFR2, p-MEK 1/2, MEK 1/2, p-ERK 1/2, ERK 1/2 and brachyury. Representative bands from three independent experiments are shown. ( C , D and E ) JHC7 and UCH1 cells were seeded in 96-well plate in at least triplicate and treated with FGF2 (100ng/ml) for 48h (C D) or 5 days (E) followed by PD173074 (1 µM) for 30min. Caspase 3 activity (C), DNA fragmentation (D) and cell growth (E) were measured by the Caspase-GloR 3/7 assay, a DNA Cell Death Detection ELISA PLUS Kit and MTS assay. Values represent means ± SD ( n = 3 for DNA fragmentation and cell growth, n = 4 for caspase 3 activity).* P

    Journal: Carcinogenesis

    Article Title: The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival

    doi: 10.1093/carcin/bgu014

    Figure Lengend Snippet: The inhibition of FGFR reduced MEK/ERK phosphorylation, brachyury expression and the growth of chordoma cells. ( A ) JHC7, UCH1 and UCH2 cells were seeded in six-well plates at density of 2×10 5 cells per well for 24h, then cells were starved overnight and treated with FGF2 (100ng/ml) for 10min following PD173074 treatment (1 µM) for 30min. Cell protein extracts were used for western blot analysis of FGFR2 and its phosphorylation (p-FRS2). Representative bands from three independent experiments are shown. ( B ) JHC7, UCH1 and UCH2 cells were treated with FGFR inhibitor (PD173074) at dose of 0.5, 1 and 2 µM for 48h. Cell protein extracts were used for western blot analysis of p-FRS2-α, FGFR2, p-MEK 1/2, MEK 1/2, p-ERK 1/2, ERK 1/2 and brachyury. Representative bands from three independent experiments are shown. ( C , D and E ) JHC7 and UCH1 cells were seeded in 96-well plate in at least triplicate and treated with FGF2 (100ng/ml) for 48h (C D) or 5 days (E) followed by PD173074 (1 µM) for 30min. Caspase 3 activity (C), DNA fragmentation (D) and cell growth (E) were measured by the Caspase-GloR 3/7 assay, a DNA Cell Death Detection ELISA PLUS Kit and MTS assay. Values represent means ± SD ( n = 3 for DNA fragmentation and cell growth, n = 4 for caspase 3 activity).* P

    Article Snippet: Human FGF2 ELISA Kit was from Sigma–Aldrich Co. LLC (St Louis, MO).

    Techniques: Inhibition, Expressing, Western Blot, Activity Assay, Enzyme-linked Immunosorbent Assay, MTS Assay

    Effects of nephrectomy and/or high phosphorus diet on serum levels of systemic bone formation and skeletal markers. Serum levels of ( a ) Calcium, ( b ) sclerostin, ( c ) phosphorus, ( d ) creatinine, ( e ) FGF23, and ( f ) iPTH were measured at days 19 and 26 post-nephrectomy. *Significant at p

    Journal: BMC Nephrology

    Article Title: Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism

    doi: 10.1186/s12882-018-0822-8

    Figure Lengend Snippet: Effects of nephrectomy and/or high phosphorus diet on serum levels of systemic bone formation and skeletal markers. Serum levels of ( a ) Calcium, ( b ) sclerostin, ( c ) phosphorus, ( d ) creatinine, ( e ) FGF23, and ( f ) iPTH were measured at days 19 and 26 post-nephrectomy. *Significant at p

    Article Snippet: A positive relationship between iPTH and FGF23 ( r = 0.75, r 2 = 0.56, p < 0.05; Fig. ) was also observed at day 26 after nephrectomy.

    Techniques: